The stock of Regenxbio Inc (NASDAQ:RGNX) is a huge mover today! The stock increased 7.35% or $1.5 on November 23, hitting $21.9. About 256,021 shares traded hands or 14.93% up from the average. Regenxbio Inc (NASDAQ:RGNX) has risen 94.15% since April 22, 2016 and is uptrending. It has outperformed by 88.74% the S&P500.
The move comes after 7 months positive chart setup for the $548.87 million company. It was reported on Nov, 24 by Barchart.com. We have $23.00 PT which if reached, will make NASDAQ:RGNX worth $27.44M more.
Analysts await Regenxbio Inc (NASDAQ:RGNX) to report earnings on March, 2. They expect $-0.60 EPS, down 200.00% or $0.40 from last year’s $-0.2 per share. After $-0.69 actual EPS reported by Regenxbio Inc for the previous quarter, Wall Street now forecasts -13.04% EPS growth.
Regenxbio Inc (NASDAQ:RGNX) Ratings Coverage
Out of 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $33 is the highest target while $29 is the lowest. The $31 average target is 41.55% above today’s ($21.9) stock price. Regenxbio has been the topic of 4 analyst reports since October 12, 2015 according to StockzIntelligence Inc. The stock of Regenxbio Inc (NASDAQ:RGNX) earned “Buy” rating by Chardan Capital Markets on Tuesday, October 20. The stock of Regenxbio Inc (NASDAQ:RGNX) has “Overweight” rating given on Monday, October 12 by Piper Jaffray. The stock has “Overweight” rating given by Morgan Stanley on Tuesday, October 13. The stock has “Buy” rating given by Bank of America on Monday, October 12.
According to Zacks Investment Research, “REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.”
Another recent and important Regenxbio Inc (NASDAQ:RGNX) news was published by Bizjournals.com which published an article titled: “Venture-backed Md. biotech files for IPO” on August 17, 2015.
RGNX Company Profile
REGENXBIO Inc., incorporated on July 16, 2008, is a biotechnology company. The Firm is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s AAV gene delivery platform (NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). The Company’s NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. NAV Vectors have demonstrated stable expression in animals for over eight years. In addition, AAV8 vectors have demonstrated stable expression for over four years in a clinical trial for the treatment of hemophilia B. The Firm develops products for various indications, including metabolic, neurodegenerative and retinal diseases. The Company’s therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.